(Q44371875)
Statements
1 reference
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours (English)
1 reference
A Awada
1 reference
R Thödtmann
1 reference
M J Piccart
1 reference
J Wanders
1 reference
A H G J Schrijvers
1 reference
I-M Von Broen
1 reference
A R Hanauske
1 reference
EORTC-ECSG phase I study
1 reference
1 April 2003
1 reference
1 reference
39
1 reference
6
1 reference
742-747
1 reference
Identifiers
1 reference
1 reference